(Q30359038)

17 August 2017

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. (English)

1 reference

17 August 2017

0 references

1 reference

1 reference

Cara A Mathews

3

0 references

author name string

Lisa M Landrum

1

1 reference

17 August 2017

James Java

2

1 reference

17 August 2017

Grainger S Lanneau

4

1 reference

17 August 2017

Larry J Copeland

5

1 reference

17 August 2017

Deborah K Armstrong

6

1 reference

17 August 2017

Joan L Walker

7

1 reference

17 August 2017

language of work or name

English

0 references

publication date

8 April 2013

1 reference

17 August 2017

1 reference

17 August 2017

130

1 reference

17 August 2017

1

1 reference

17 August 2017

12-18

1 reference

17 August 2017

Cancer statistics, 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Ovarian cancer in younger vs older women: a population-based analysis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Epithelial ovarian carcinoma in the reproductive age group

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870593

Intraperitoneal chemotherapy comes of age

26 November 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.001

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.001

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.001

Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.001

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.001

Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.001

The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.04.001

10.1016/J.YGYNO.2013.04.001

7 January 2021

Identifiers

DOI

1 reference

release_jthcd5htibfz5hbimqhl2es5nq

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jthcd5htibfz5hbimqhl2es5nq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

17 August 2017

PubMed publication ID

23578540

1 reference